Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2019 1
2020 1
2022 2
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Seroprevalence of Antibodies to Severe Acute Respiratory Syndrome Coronavirus 2 Among Healthcare Workers in Kenya.
Etyang AO, Lucinde R, Karanja H, Kalu C, Mugo D, Nyagwange J, Gitonga J, Tuju J, Wanjiku P, Karani A, Mutua S, Maroko H, Nzomo E, Maitha E, Kamuri E, Kaugiria T, Weru J, Ochola LB, Kilimo N, Charo S, Emukule N, Moracha W, Mukabi D, Okuku R, Ogutu M, Angujo B, Otiende M, Bottomley C, Otieno E, Ndwiga L, Nyaguara A, Voller S, Agoti CN, Nokes DJ, Ochola-Oyier LI, Aman R, Amoth P, Mwangangi M, Kasera K, Ng'ang'a W, Adetifa IMO, Wangeci Kagucia E, Gallagher K, Uyoga S, Tsofa B, Barasa E, Bejon P, Scott JAG, Agweyu A, Warimwe GM. Etyang AO, et al. Among authors: gitonga j. Clin Infect Dis. 2022 Jan 29;74(2):288-293. doi: 10.1093/cid/ciab346. Clin Infect Dis. 2022. PMID: 33893491 Free PMC article.
Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
Jenkin D, Wright D, Folegatti PM, Platt A, Poulton I, Lawrie A, Tran N, Boyd A, Turner C, Gitonga JN, Karanja HK, Mugo D, Ewer KJ, Bowden TA, Gilbert SC, Charleston B, Kaleebu P, Hill AVS, Warimwe GM. Jenkin D, et al. Among authors: gitonga jn. Lancet Infect Dis. 2023 Aug;23(8):956-964. doi: 10.1016/S1473-3099(23)00068-3. Epub 2023 Apr 13. Lancet Infect Dis. 2023. PMID: 37060917 Free PMC article. Clinical Trial.
FINDINGS: Between June 11, 2021, and Jan 13, 2022, 15 volunteers received a single dose of either 5 10(9) vp (n=3), 2.5 10(10) vp (n=6), or 5 10(10) vp (n=6) ChAdOx1 RVF. Nine participants were female and six were male. 14 (93%) of 15 participants reported so …
FINDINGS: Between June 11, 2021, and Jan 13, 2022, 15 volunteers received a single dose of either 5 10(9) vp (n=3), 2.5 10(10) vp ( …
Congenital microcephaly unrelated to flavivirus exposure in coastal Kenya.
Barsosio HC, Gitonga JN, Karanja HK, Nyamwaya DK, Omuoyo DO, Kamau E, Hamaluba MM, Nyiro JU, Kitsao BS, Nyaguara A, Mwakio S, Newton CR, Sang R, Wright D, Sanders EJ, Seale AC, Agoti CN, Berkley JA, Bejon P, Warimwe GM. Barsosio HC, et al. Among authors: gitonga jn. Wellcome Open Res. 2019 Nov 15;4:179. doi: 10.12688/wellcomeopenres.15568.1. eCollection 2019. Wellcome Open Res. 2019. PMID: 32175480 Free PMC article.
Results: Of the 11,061 newborns, 214 (1.9%, 95%CI 1.69, 2.21) had microcephaly. Microcephaly prevalence was 1.0% (95%CI 0.64, 1.70, n=1529) and 2.1% (95%CI 1.81, 2.38, n=9532) in the scanned and LMP cohorts, respectively. After excluding babies <2500 g (n= …
Results: Of the 11,061 newborns, 214 (1.9%, 95%CI 1.69, 2.21) had microcephaly. Microcephaly prevalence was 1.0% (95%CI 0.64, 1.70, n …
An optimization of four SARS-CoV-2 qRT-PCR assays in a Kenyan laboratory to support the national COVID-19 rapid response teams.
Mohammed KS, de Laurent ZR, Omuoyo DO, Lewa C, Gicheru E, Cheruiyot R, Bartilol B, Mutua S, Musyoki J, Gumba H, Mwacharo J, Riako D, Mwangi SJ, Gichuki BM, Nyamako L, Karani A, Karanja H, Mugo D, Gitonga JN, Njuguna S, Gumbi W, Tawa B, Tendwa M, Cheruiyot W, Sein Y, Nyambu JK, Patta SO, Thani TS, Maitha EK, Kitole B, Mwakinangu MS, Muslih BS, Otieno JO, Nyiro JU, Kiyuka P, Ndwiga L, Wamae K, Kimani D, Makale J, Morobe JM, Osoti V, Lambisia AW, Odundo C, Mwarumba S, Mutunga M, Bejon P, Tsofa B, Agoti CN, Ochola-Oyier LI. Mohammed KS, et al. Among authors: gitonga jn. Wellcome Open Res. 2022 Mar 4;5:162. doi: 10.12688/wellcomeopenres.16063.2. eCollection 2020. Wellcome Open Res. 2022. PMID: 35330938 Free PMC article.
All the assays had optimal performance when the primers and probes were used at 0.375X, except for the Berlin N gene assay. The DAAN kit was a reliable assay for primary screening of SARS-CoV-2 whereas the BGI kit's performance was dependent on the volumes and concentratio …
All the assays had optimal performance when the primers and probes were used at 0.375X, except for the Berlin N gene assay. The DAAN …
Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in HIV-infected people in Kenya (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
Kimathi D, Juan-Giner A, Orindi B, Grantz KH, Bob NS, Cheruiyot S, Hamaluba M, Kamau N, Fall G, Dia M, Mosobo M, Moki F, Kiogora K, Chirro O, Thiong'o A, Mwendwa J, Guantai A, Karanja HK, Gitonga J, Mugo D, Ramko K, Faye O, Sanders EJ, Grais RF, Bejon P, Warimwe GM. Kimathi D, et al. Among authors: gitonga j. Lancet Infect Dis. 2023 Aug;23(8):974-982. doi: 10.1016/S1473-3099(23)00114-7. Epub 2023 Apr 28. Lancet Infect Dis. 2023. PMID: 37127045 Free PMC article. Clinical Trial.
Fractional dosing therefore met the non-inferiority criterion, and non-inferiority was maintained for 1 year. The most common adverse events were headache (n=31 [12%]), fatigue (n=23 [9%]), myalgia (n=23 [9%]), and cough (n=14 [6%]). ...
Fractional dosing therefore met the non-inferiority criterion, and non-inferiority was maintained for 1 year. The most common adverse events …
SARS-CoV-2 seroprevalence and implications for population immunity: Evidence from two Health and Demographic Surveillance System sites in Kenya, February-December 2022.
Kagucia EW, Ziraba AK, Nyagwange J, Kutima B, Kimani M, Akech D, Ng'oda M, Sigilai A, Mugo D, Karanja H, Gitonga J, Karani A, Toroitich M, Karia B, Otiende M, Njeri A, Aman R, Amoth P, Mwangangi M, Kasera K, Ng'ang'a W, Voller S, Ochola-Oyier LI, Bottomley C, Nyaguara A, Munywoki PK, Bigogo G, Maitha E, Uyoga S, Gallagher KE, Etyang AO, Barasa E, Mwangangi J, Bejon P, Adetifa IMO, Warimwe GM, Scott JAG, Agweyu A. Kagucia EW, et al. Among authors: gitonga j. Influenza Other Respir Viruses. 2023 Sep;17(9):e13173. doi: 10.1111/irv.13173. Influenza Other Respir Viruses. 2023. PMID: 37752065 Free PMC article.
RESULTS: HDSS residents were sampled in February-June 2022 (Kilifi HDSS N = 852; Nairobi Urban HDSS N = 851) and in August-December 2022 (N = 850 for both sites). ...
RESULTS: HDSS residents were sampled in February-June 2022 (Kilifi HDSS N = 852; Nairobi Urban HDSS N = 851) and in August-Dec …
Safety and immunogenicity of ChAdOx1 nCoV-19 (AZD1222) vaccine in adults in Kenya: a phase 1/2 single-blind, randomised controlled trial.
Hamaluba M, Sang S, Orindi B, Njau I, Karanja H, Kamau N, Gitonga JN, Mugo D, Wright D, Nyagwange J, Kutima B, Omuoyo D, Mwatasa M, Ngetsa C, Agoti C, Cheruiyot S, Nyaguara A, Munene M, Mturi N, Oloo E, Ochola-Oyier L, Mumba N, Mauncho C, Namayi R, Davies A, Tsofa B, Nduati EW, Aliyan N, Kasera K, Etyang A, Boyd A, Hill A, Gilbert S, Douglas A, Pollard A, Bejon P, Lambe T, Warimwe G; COV004 Vaccine Trial Group. Hamaluba M, et al. Among authors: gitonga jn. Wellcome Open Res. 2023 Nov 27;8:182. doi: 10.12688/wellcomeopenres.19150.2. eCollection 2023. Wellcome Open Res. 2023. PMID: 38707489 Free PMC article.
RESULTS: Between 28 (th) October 2020 and 19 (th) August 2021, 400 participants were enrolled and assigned to receive ChAdOx1 nCoV-19 (n=200) or rabies vaccine (n=200). Local and systemic adverse events were self-limiting and mild or moderate in nature. ...
RESULTS: Between 28 (th) October 2020 and 19 (th) August 2021, 400 participants were enrolled and assigned to receive ChAdOx1 nCoV-19 (n …
Menstruation requirements as a barrier to contraceptive access in Kenya.
Stanback J, Nutley T, Gitonga J, Qureshi Z. Stanback J, et al. Among authors: gitonga j. East Afr Med J. 1999 Mar;76(3):124-6. East Afr Med J. 1999. PMID: 10442109
In contrast, information from clinic registers and client records in the same nine clinics showed that the (weighted) proportion of registered new clients who were menstruating was 85% (n = 102). We estimated that 78% of non-menstruating women (35% of all potential new cli …
In contrast, information from clinic registers and client records in the same nine clinics showed that the (weighted) proportion of register …